

# PROVIDER Update



CONTRACTUAL | JANUARY 10, 2025 | UPDATE 25-019 | 5 PAGES

## New: 4th Quarter 2024 Injectable Medication HCPCS/DOFR Crosswalk

### Use the updates for dates of service on and after March 18, 2025

The Health Net\* Pharmacy Advisory Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, effective March 18, 2025 are listed on pages 2-5 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- 23 new injectable medications to be added to the DOFR crosswalk.
- 11 updates and changes to current injectable medication procedure codes.
- 2 updated categories.
- 7 updates for new generic drugs.

### Additional information

Relevant sections of Health Net's provider operations manuals will be revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at [provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com) > *Provider Library under Quick Links*, or go directly to [providerlibrary.healthnetcalifornia.com](https://providerlibrary.healthnetcalifornia.com).

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center listed in the right-hand column.

### THIS UPDATE APPLIES TO:

- Participating Physician Groups

### LINES OF BUSINESS:

- IFP
  - Ambetter HMO
  - Ambetter PPO
- Employer Group
  - HMO/POS
  - PPO
- Wellcare By Health Net
  - Medicare Advantage (HMO)
  - Medicare Advantage (PPO)
- Medi-Cal
  - Amador
  - Calaveras
  - Inyo
  - Los Angeles
    - Molina
  - Mono
  - Sacramento
  - San Joaquin
  - Stanislaus
  - Tulare
  - Tuolumne

### PROVIDER SERVICES

[provider\\_services@healthnet.com](mailto:provider_services@healthnet.com)

**Ambetter from Health Net IFP**  
**Ambetter HMO** – 888-926-2164

**Ambetter from Health Net IFP**  
**Ambetter PPO** – 844-463-8188

**Health Net Employer Group**  
**HMO, POS & PPO** – 800-641-7761

**Medicare (individual & employer group)**  
**(Wellcare By Health Net)** – 800-929-9224

**Medi-Cal (including CS and ECM providers)**  
– 800-675-6110

### PROVIDER PORTAL

[provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com)

### PROVIDER COMMUNICATIONS

[provider.communications@healthnet.com](mailto:provider.communications@healthnet.com)

\*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at [provider.communications@healthnet.com](mailto:provider.communications@healthnet.com) indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

## Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

### New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
<b>J3590</b>	Aucatzyl®	Obecabtagene autoleucel suspension for intravenous infusion	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>TBD</b>	Audenz™	Influenza A (H5N1) tiss-cult subunit adjuvanted IM emulsion	Therapeutic injection	Immunization
<b>J3490</b>	Bridion®	Sugammadex injection for intravenous use. Initial United States approval 2015	Therapeutic injection	
<b>C9399</b>	Cytelzo®	Adalimumab-adbm; Low Conc., interchangeable	Self-injectable	
<b>J3590</b>	Ebglyss™	Lebrikizumab-lbkz subcutaneous solution auto-injection 250 mg/2ml	Self-injectable	
<b>J3490</b>	Enzeevu™	Aflibercept-abzv	Therapeutic injection	
<b>J9301</b>	Gazyva®	Obinutuzumab injection, for intravenous use	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J9248</b>	Hepzato kit™	Melphalan for intra-arterial solution 59 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J3590</b>	Hympavzi™	Marstacimab-hncq injection, for subcutaneous use	Self-injectable	Blood/blood products for hemophilia
<b>J9999</b>	Lymphir™	Denileukin diftitox-cxdl	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J3590</b>	Nemluvio®	Nemolizumab-ilto 30 mg auto-injector	Self-injectable	
<b>J3590</b>	Niktimvo™	Axatilimab-csfr	Therapeutic injection	
<b>J3590</b>	Ocrevus zunovo™	Ocrelizumab hyaluronidase-ocsq	Therapeutic injection	
<b>J3590</b>	Pavblu™	Aflibercept-ayyh intravitreal injection 2 mg/0.05 mL	Therapeutic injection	
<b>J3590</b>	Piasky®	Crovalimab-akkz injection, for intravenous or subcutaneous	Therapeutic injection	

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

## New drugs, continued

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9999	Tecelra®	Afamitresgene autoleucel IV suspension 10,000,000,000 cells	Therapeutic injection	Chemotherapy <sup>1</sup>
J9999	Tecentriq hybreza™	Atezolizumab hyaluronidase-tqjs injection 1875-30000 mg-unit/15 mL	Therapeutic injection	Chemotherapy <sup>1</sup>
J1628	Tremfya® IV	Guselkumab injection for intravenous use	Therapeutic injection	
Q5135	Tyenne®	Tocilizumab-aazg injection for intravenous or subcutaneous use	Therapeutic injection	Home health/ Infusion <sup>2</sup>
J3490	Yorvipath®	Palopegteriparatide injection for subcutaneous use	Self-injectable	
J9999	Vyloy®	Zolbetuximab-clzb for IV solution 100 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
J3590	Yuflyma®	Adalimumab-aaty; high concentration	Self-injectable	
J3490	Zurnai™	Nalmefene injection, for intramuscular or subcutaneous use	Self-injectable	

## Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
C9167	Adzynma®	Injection, ADAMTS13, recombinant-krhn, 10 international units (IU)	Code deletion
C9172	Beqvez™	Fidanacogene elaparvovec-dzkt injection, for intravenous infusion	Replaces J3590
C9166	Cosentyx®	Injection, secukinumab, intravenous, 1 mg	Code deletion
J1170	Hydromorphone	Injection, hydromorphone, up to 4 mg	Code deletion
J2001	Lidocaine	Injection, lidocaine hydrochloride for intravenous infusion, 10 mg	Code deletion
J9371	Marqibo®	Injection, vincristine sulfate liposome, 1 mg	Code deletion

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

<sup>2</sup>When administered by a nurse in a home setting.

---

**Updates/changes to injectable medication procedure codes or medications, *continued***

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Comment</b>
<b>J2470</b>	Pantoprazole	Injection, pantoprazole sodium, 40 mg	Code deletion – replaces S0164
<b>J2470</b>	Pantoprazole	Injection, pantoprazole sodium, per vial	Code deletion – replaces C9113
<b>J9258</b>	Paclitaxel protein-bound particles	Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to J9264, 1 mg	Code deletion
<b>J2780</b>	Ranitidine	Injection, ranitidine hydrochloride, 25 mg	Code deletion
<b>J9329</b>	Tevimbra®	Tislelizumab-jsgr injection, for intravenous use	Replaces J3590

**Category changes**

The following medications have been approved to correct the secondary category listed below.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J0485</b>	Nulojix®	Belatacept, 1 mg injection	Therapeutic injection	Transplant
<b>J1932</b>	Lanreotide 1 mg (Cipla)	Lanreotide acetate, 1 mg	Therapeutic injection	Chemotherapy adjunctive <sup>1</sup>

**New generic injectable medications**

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J0893</b>	Decitabine	Injection, decitabine (sun pharma), not therapeutically equivalent to J0894	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J9393</b>	Fulvestrant	Injection, fulvestrant (teva), not therapeutically equivalent to J9395, 25 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J0651</b>	Levothyroxine	Injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to J0650, 10 mcg	Therapeutic injection	

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

---

**New generic injectable medications, *continued***

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J0652</b>	Levothyroxine	Injection, levothyroxine sodium (Hikma), not therapeutically equivalent to J0650, 10 mcg	Therapeutic injection	
<b>J0650</b>	Levothyroxine	Levothyroxine sodium not otherwise specified injection, 10 mcg	Therapeutic injection	
<b>J9296</b>	Pemetrexed	Injection, pemetrexed (Accord), not therapeutically equivalent to J9305, 10 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J9314</b>	Pemetrexed	Injection, pemetrexed teva, not therapeutically equivalent to J9305, 10 mg	Therapeutic injection	Chemotherapy <sup>1</sup>

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at [www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html](http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html)

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.